Home / Market News / $ALT
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Altimmune Reports Third Quarter 2026 Financial Results

Nov 12, 2026, 2:10 PM UTC · Primary ticker $ALT

Altimmune reported its Q3 2026 financial results, highlighting a strong cash position of $480 million and increased R&D expenses due to ongoing clinical trials for MASH and ALD. The company also noted key clinical milestones for pemvidutide, including Breakthrough Therapy Designation and publication of Phase 2b data, reinforcing its liver disease strategy.

Altimmune reported its third-quarter 2026 financial results, showing a healthy cash balance of $480 million, which provides a solid runway for its ongoing clinical programs. Research and development expenses significantly increased, reflecting accelerated investment in the PERFORMA Phase 3 trial for MASH and the RESTORE Phase 2 trial for ALD, indicating progress in its pipeline. The FDA's Breakthrough Therapy Designation for pemvidutide in MASH and the publication of positive Phase 2b data are significant de-risking events, bolstering confidence in the lead candidate. This news is positive for Altimmune (ALT) as it demonstrates financial stability and clinical advancement, potentially attracting investor interest in its liver disease franchise. The short-term implication is likely positive sentiment, while long-term success hinges on the outcomes of these pivotal trials.

$ALT positive Strong cash position, clinical trial progress, FDA designation
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.